Acutely psychotic schizophrenic patients were maintained on debrisoquin (DBQ) throughout 5 weeks of treatment with haloperidol. Treatment with haloperidol caused initial increases in urinary homovanillic acid (HVA) output that returned toward baseline by the 5th week. During haloperidol treatment, plasma levels of HVA tended to decrease, concurrent with increased renal cltll rance of HV A. Plasma 3-methoxy-4-hydroxyphenyl-
glycol (MHPG) levels and urinary MHPG output both decreased over the course of treatment. The differences in HVA and MHPG metabolism suggest differential effects of treatment on dopamine and norepinephrine systems. Neuroleptic treatment also abolished the marked morning decreases in plasma HVA concentrations (reported in part D. [Neuropsychopharmacology 8:111-116, 1993J and 3-methoxy-4-hydroxyphenylglycol (MHPG), were noted. The data in the preceding paper focused on in formation obtained from schizophrenic/psychotic pa tients prior to the administration of neuroleptic drugs.
In this paper we present data on HV A and MHPG in plasma and urine while a subset of the patients de scribed in the preceding paper were undergoing a 5-week trial on haloperidol. Only data from patients who were able to complete the entire treatment period are reported here.
METHODS
Subject selection, subject characteristics, analytic chem ical methods, materials, and statistical procedures were the same as those described in the previous paper that dealt with pretreatment amine metabolites. In this study, after all of the pretreatment procedures described in the preceding paper, the patients continued receiv ing 10 mg of DBQ four times daily (40 mg/day) and in addition were treated with 10 mg of haloperidol three times daily. Anticholinergics were given only on an as needed basis. At weekly intervals, for 5 weeks, patients had blood samples drawn at 8:00 A.M. and 10:00 A.M. and 3.5-hour urine specimens collected under super-vision as previously noted. Behavior ratings (types de scribed in previous paper) were also obtained. Because of the relatively high dose of haloperidol, as well as clin ical factors associated with nonresponse, some patients did not enter and others did not complete the treatment phase of these studies. At the end of 5 weeks of treat ment with haloperidol the patients were again chal lenged with placebo, apomorphine, or a neuroleptic, using the procedures described in the preceding paper. In this present paper, however, only the data obtained with the placebo will be reported. The other challenge data will be reported elsewhere.
For comparison purposes we used two different baseline days to compare weekly results during 5 weeks of treatment with haloperidol. The fIrst was the base line data of the patients after 7 days receiving DBQ. The second is the baseline of the control subjects after 7 days receiving DBQ. The particular baseline used for a given comparison is referred to in the text.
Statistical Analysis
The change-over time in plasma HV A and MHPG during the placebo challenge day before and after neuroleptic treatment was analyzed using one-way repeated-mea sures analysis of variance (ANOVA). Repeated-measures ANOV A with two repeated factors, time and day inter action was used to compare the time response on the two placebo days (i.e., before and after neuroleptic treat ment). A similar one-way repeated-measures ANOVA was used to compare levels of plasma and urinary me tabolites during 5 weeks of neuroleptic treatment. To obtain some measure of whether patient metabolite values during the haloperidol treatment decreased to "normal" levels, we have plotted the patient data (as mean ± SEM) against a 95% confIdence interval for the mean of normal subjects, using the baseline of the con trol subjects after 7 days receiving DBQ. Urinary HV A (Fig. 2) was increased by the 1st and ---) and 95% confIdence interval
The effects of neuroleptic treatment on renal clear anceofHVA during the 5-week treatment period were cal culated. An overall ANOV A with repeated measures was SignifIc ant (p = 0.044). For the individual contrasts paired I-te sts were used ( Table 1 ). The 5 weeks of neu roleptic treatment were associated with a signifIcant in crease in the renal clearance of plasma HV A from the patients' own baseline levels at weeks 1, 3, and 4. This increase in renal clearance of HV A would be expected 10 increase urinary HV A values and to decrease plasma HVA concentrations, and it is thus of interest that pl asma HV A tended to fall during haloperidol treatment and urinary HV A initially increased. However, renal clearance was not signifIcantly different from baseline during the 5th week of treatment but plasma HV A con- Values are expressed as milliliters per minute ± SO. The num ber of subjects was eight. The p-values are for the comparison of each time point with baseline by paired t -tests. The overall repeated measures ANOVA was signifIcant (df, = 5; F = 2.56, P = 0.04, n = 8).
centration tended toward being lower than the patients' (but not the controls') baseline. These fIndings are con sistent with an initial increase and then a decline in DA synthesis and with an increase in renal clearance as sociated with haloperidol administration. For reasons noted in the preceding paper, calculations for renal clearance of MHPG are not meaningful.
Results with the Placebo Pharmacologic Challenge
Repeated after 5 weeks of Haloperidol Treatment
As noted earlier, challenge tests with placebo, apomor phine, and haloperidol were given to patients who had ceased treatment with neuroleptics and again after 5 weeks of receiving haloperidol. Only the placebo data are presented here. After haloperidol treatment the pre viously noted strong time effect for plasma HV A was no longer seen ( Table 2 ). The time curve for plasma HV A after 5 weeks of haloperidol treatment is some what flattened out. Overall, plasma HV A levels did not differ signifIcantly between the two challenge days. In addition, values (not shown) for plasma MHPG were compared between the fIrst and second challenges.
Plasma MHPG values were lower during challenge 2 than during challenge 1 (p = 0.01), but were still higher than controls. The strong time effect seen before haloperidol (reported in paper I) was not seen after 5 weeks of haloperidol treatment, although challenge 1 did not differ from challenge 2 when an ANOV A with repeated measures was done. Values for plasma HV A are expressed as nanograms per milliliter, mean ± SO.
Correlations between behavioral ratings and bio chemical changes during treatment with haloperidol were not done because of the small number of patients completing the 5-week haloperidol treatment.
DISCUSSION
The time course of plasma HV A and MHPG levels af ter institution of neuroleptic treatment has been charac terized by a number of investigators. With regard to plasma HV A, these reports are somewhat inconsistent regarding the effects during the fIrst days of neurolep tic treatment, but the fInding of a downward trend over weeks of treatment as reported here is quite uniform (Pickar et al. 1984 (Pickar et al. , 1986 Doran et al. 1985 Doran et al. , 1990 Chang et al. 1988 Chang et al. , 1990 Davila et al. 1988; Farde et al. 1988; Alfredsson and Wiesel 1989; Bowers et al. 1989; David son et al. 1991) . Another effect of chronic neuroleptic treatment, as noted here, which has also been reported by others is the normal diurnal variation of plasma HV A levels seen in unmedicated patients and control sub jects. A number of investigators have reported that plasma HV A levels decreased during the late morning hours from about 8:00 A.M. to noon (Contreras et al. 1988; Davidson et al. 1988; Sack et al. 1988; Davila et al. 1989; Doran et al. 1990 ). Also consistent with this report, others have found that chronic neuroleptic treat ment tends to lessen or abolish this diurnal decline in plasma HV A levels (Davila et al. 1989; Doran et al. 1990 ).
These fIndings could be interpreted as reflecting de creased DA turnover. Our observations with regard to urinary output of HV A, however, do not support this interpretation. Urinary HV A output tended to increase during the fIrst few weeks of haloperidol treatment and, even after 5 weeks, had not decreased. Increased urine HV A output after haloperidol treatment has been pre viously reported by us (Contreras et al. 1987 (Contreras et al. , 1988 . The apparent discrepancy between plasma HV A levels and urinary HV A output might be explained by the demon strated increased clearance of HV A from plasma (Ta ble 1). Thus, our data are at least in part consistent with the interpretation that two changes occurred during the haloperidol treatment period. First, DA turnover ini tially increases, as reflected in increased urinary HVA output (this study and Contreras et al. 1987 and Contreras et al. , 1988 , and in an increase in cerebrospinal fluid (CSF) HV A (Bowers 1974; Gerlach et al. 1975; van Praag and Korf 1975; Bjer kenstedt et al. 1979; Beckmann et al. 1983; Doran et al. 1989 ), but tolerance to this effect develops, as reflected in normalization of urine HV A output (this study) and in CSF HVA (Rimon et al. 1971; Gerlach et al. 1974; Bowers and Heninger 1981; Post and Goodwin 1975) . Second, during the treatment phase, renal clearance of HV A increases. Effects of dopaminergic and DA blocking agents on renal HV A clearance and on renal NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.2 plasma flow have been noted by others (Yeh et al. 196� Israel et al. 1986; Potter et al. 1989) , but this evidence suggests that neuroleptic agents acutely reduce renal plasma flow, which should decrease HV A clearance. Therefore, it is not clear if the changes in HV A cl ear· ance are due to haloperidol or to other factors.
The observations with regard to plasma MHPG lev· els and urinary MHPG output were more straightfor . ward. During the course of haloperidol treatment plasma levels and urinary output decreased over 5 weeks. These decreases presumably reflected decreased CNS NE turnover. In earlier work, Joseph et al. (1976) found that favorable clinical outcome was associated with a reduction in urinary MHPG during neuroleptic treatment. Alfredsson and Wiesel (1989) found that plasma MHPG decreased signifIcantly each week after starting sulpiride. In all these studies other major me tabolites of NE were not measured, and the possibility exists that there was shunting of metabolism away from MHPG toward these other metabolites.
There is evidence that much of the HV A in plasma and urine is from metabolism of DA in noradrenergic neurons (Anden and Grabowska-Anden 1983; Anden et al. 1985; Scheinin et al. 1984; Scheinin 1986; Schei nin and Virtanen 1986; Kopin et al. 1988a,b,c) . In our haloperidol-treated patients, urinary HV A and MHPG changed in opposite directions over the fIrst several weeks. Since a decrease in MHPG would normally be associated with a concurrent decrease in HV A (Kopin et al. 1988a) , the observed increase in urinary HV A gives a minimal estimate of increased DA metabolism, i.e., if NE turnover were decreased as much as is indicated by the decreases in MHPG, then DA turnover must have been substantially increased in order to produce the moderate initial increases in urinary HV A that were actually present during neuroleptic treatment.
In the work reported in the preceding paper and in earlier work (Contreras et al. 1988 ), we found a con siderable decrease in plasma HV A concentration be tween the hours of 8:00 A.M. and noon in control sub jects and unmedicated schizophrenics. This time course has been noted by others as well (Sack et al. 1988; Davila et al. 1989; Doran et al. 1990) . It was of interest to deter mine if this diurnal rhythm was affected by haloperidol treatment. As noted in Table 2 , this morning decrease in plasma HV A levels was abolished by the end of the 5th week of haloperidol treatment. This fInding has re cently been published by Doran et al. (1990) . Its signifI cance with regard to the mechanism of action of halo peridol is unknown.
During the time that the work reported here was being completed, it was reported that very long-term neuroleptic administration may affect hydroxylation of DBQ in mentally retarded persons (Syvalahti et aI. 1986 ). These authors found that the ratio of DBQ to 4-0H DBQ was signifIcantly raised by administration 01 a variety of neuroleptic drugs over many months. This report raised the question of whether chronic neu roleptic administration to patients receiving DBQ could raise the effective concentration of DBQ and thereby alter its effects on monoamine metabolism. In our work we used a high-performance liquid chromatography method to assay DBQ and 4-0H DBQ in urine and plasma in patients who were initially treated with DBQ alo ne and then received both DBQ and haloperidol. We found that in urine, DBQ concentrations did increase signifIcantly while patients were receiving haloperidol. However, there was a trend in the same direction for WH DBQ and we found no signifIcant effects of haloperidol on the DBQ/4-0H DBQ ratio. Our results agree with the possibility raised by Syvalahti et aI. (1986) as to DBQ levels being affected by the administration of neuroleptic agents, but also indicate that the ratio of DBQ/4-0H DBQ is not altered. This suggests that the un derlying mechanism of the neuroleptic effect is probably not on hydroxylation. Even though DBQ lev els ma y have increased during haloperidol treatment, it see ms somewhat unlikely that such an increase would have signihcantly influenced the results. In earlier work, we found that increasing the dose of DBQ from 40 mg/day (as used here) to 60 mg/day did not further de crease HV A concentrations in plasma or urine (Maas et al. 1985) . Moreover, our fmding of decreases in plasma HV A during haloperidol treatment are consis tent with the reports of others who studied patients not receiving DBQ. In addition, we found an increase in uri nary HV A output during haloperidol treatment, which would certainly not be attributable to greater monoamine oxidase inhibition by DBQ. For these rea sons, we conclude that the effects of haloperidol on catecholamine metabolite plasma levels and urinary ex cretion were not attributable to its effect on DBQ levels. 
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